An inflammatory Signature of Glucose Impairment in Cystic Fibrosis.
cystic fibrosis-related diabetes
cytokines
growth factors
immune mediators
impaired glucose tolerance
inflammation
Journal
Journal of inflammation research
ISSN: 1178-7031
Titre abrégé: J Inflamm Res
Pays: New Zealand
ID NLM: 101512684
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
03
2022
accepted:
09
08
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
Cystic fibrosis-related diabetes (CFRD) is a severe complication associated with increased morbidity and mortality in cystic fibrosis (CF) patients. Extensive inflammatory state in CF leads to pancreas damage and insulin resistance with consequent altered glucose tolerance and CFRD development. The aim of the present study was to identify circulating levels of inflammatory markers specifically associated with impaired glucose tolerance (IGT) and overt CFRD in a sample of young adults with CF. Sixty-four CF outpatients, without evident active pulmonary exacerbation, infectious and autoimmune diseases, were enrolled in the study and the levels of 45 inflammatory serum mediators were measured through x magnetic bead panel multiplex technology. Serum levels of PDGF-AA, CCL20/MIP3α, IFNα, CCL11/eotaxin, CXCL1/GROα, GMCSF, B7H1/PDL1, IL13, IL7, VEGF, and TGFα were all significantly ( Our findings suggest that increased levels of specific circulating inflammatory mediators are directly associated with impaired glucose tolerance in CF patients, thus, potentially implicating them in CFRD pathogenesis and warranting larger longitudinal studies to validate their monitoring as predictor of CFRD onset.
Identifiants
pubmed: 36238762
doi: 10.2147/JIR.S365772
pii: 365772
pmc: PMC9553277
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5677-5685Informations de copyright
© 2022 Montemari et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
EBioMedicine. 2018 Oct;36:367-375
pubmed: 30269996
PLoS One. 2018 Jan 11;13(1):e0191040
pubmed: 29324807
Cell Physiol Biochem. 2015;36(6):2340-56
pubmed: 26279438
Exp Eye Res. 2011 Oct;93(4):350-4
pubmed: 21354136
Diabetologia. 2018 Mar;61(3):636-640
pubmed: 29305625
Respir Care. 2020 Feb;65(2):233-251
pubmed: 31772069
Pediatr Pulmonol. 2019 Nov;54 Suppl 3:S84-S96
pubmed: 31715083
Nat Rev Immunol. 2010 Dec;10(12):826-37
pubmed: 21088683
Sci Rep. 2017 Dec 8;7(1):17231
pubmed: 29222447
Clin Med Insights Endocrinol Diabetes. 2019 May 28;12:1179551419851770
pubmed: 31191067
J Cyst Fibros. 2020 May;19(3):476-482
pubmed: 32115389
ERJ Open Res. 2021 Jan 18;7(1):
pubmed: 33532475
JCI Insight. 2019 Mar 21;4(6):
pubmed: 30763282
Biochem Biophys Res Commun. 2019 Aug 20;516(2):402-407
pubmed: 31217075
Life Sci. 2021 Mar 1;268:118959
pubmed: 33383045
J Int Med Res. 2019 Nov;47(11):5584-5592
pubmed: 31547733
PLoS One. 2017 Jul 28;12(7):e0182359
pubmed: 28753646
Blood. 2018 Sep 13;132(11):1146-1158
pubmed: 30054295
Mol Med Rep. 2020 Oct;22(4):2733-2740
pubmed: 32945388
Am J Physiol Endocrinol Metab. 2014 May 1;306(9):E1077-84
pubmed: 24619879
Nat Med. 2002 Jul;8(7):702-10
pubmed: 12053176
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669939
Pediatr Rev. 2001 Aug;22(8):257-64
pubmed: 11483851
Clin Lab. 2013;59(1-2):133-7
pubmed: 23505918
Ann Allergy Asthma Immunol. 2010 Jan;104(1):66-72
pubmed: 20143648
Pediatr Diabetes. 2018 Oct;19 Suppl 27:64-74
pubmed: 30094886
Pulm Circ. 2015 Mar;5(1):101-16
pubmed: 25992275
J Asthma Allergy. 2014 Apr 25;7:67-75
pubmed: 24851055
Diabet Med. 2019 Sep;36(9):1075-1081
pubmed: 31199005